Evolocumab
ACC 2015 Evolocumab effective in elderly patients; no safety issues
Treatment with the PCSK9 inhibitor evolocumab was effective in elderly patients (³65 years and ³75 years) with a side effect profile similar to placebo, according to the results of pooled analysis of nearly 2,000 patients from Phase 2, 3 and open-label studies. These findings specifically…
read more »
Overlap between HoFH and severe FH and implications for evolocumab
The implications of the overlap between homozygous hypercholesterolaemia and severe familial hypercholesterolaemia (FH) – two genetic disorders characterised by very high levels of low density lipoprotein cholesterol (LDL-C) – should be considered when selecting treatment. Professor Frederick Raal discusses the issue.
read more »
ACC 2015 More safety data with PCSK9 inhibitors: patients with very low LDL-C
Accumulating data with both alirocumab and evolocumab have so far not indicated specific safety issues. In the latest reports at ACC 2015, there were no safety signals in more than 5,000 patients who achieved very low low-density lipoprotein (LDL) cholesterol levels (<25 or <15 mg/dL)…
read more »
PROFICIO: Evolocumab reduces Lp(a) in statin-treated patients
In a pooled analysis of 4 phase 2 trials including more than 1300 patients, treatment with the PCSK9 monoclonal antibody evolocumab led to dose-related reductions in Lp(a) which were sustained during longer-term therapy. The pooled population (n=1,359) had a mean age of 56.4 (11.7) years,…
read more »
